Balance sheet as of December 31, 2011

Profit and loss account year ended December 31, 2011

Introduction

In 2011, Alzheimer Europe had an audited income of EUR 1.240,751.74 of which EUR 715,693.85 (57.68%) were for the organisation’s core activities (including the organisation’s Dementia Ethics Network and Annual Conference), EUR 207,012.08 (16.681%) were for the organisation’s public affairs activities and EUR 318,045.81 (25.63%) for the organisation’s “Value of diagnosis” project.

Funding of core activities (EUR 715,693.85)

In 2011, the core funding of Alzheimer Europe was composed as follows:

• EUR 226,697.71 (31.68%) from public funding,
• EUR 196,874.09 (27.51%) from member organisations,
• EUR 110,406.35 (15.43%) from deferred income brought forward from the financial year 2010,
• EUR 81,714.30 (11.42%) from individuals,
• EUR 60,500 (8.45%) from corporate sources,
• EUR 28,600 (4.00%) from foundations and other non-profit organisations,
• EUR 9,061.13 (1.27%) from other sources and
• EUR 1,840.27 (0.26%) from bank interest and similar.

Public funding

In 2011, the breakdown of public funding totalling EUR 226,697.71 can be broken down as follows:

• Alzheimer Europe received EUR 189,703.52 as an operating grant from the European Commission, EUR 19,940.63 for its participation in the PharmaCog project and EUR 17,053.56 for its participation in the DECIDE project.

Funding from member organisations

In 2010, the EUR 196,874.09 funding from member organisations can be broken down as follows:

• EUR 87,587.49 from the Luxembourg member organisation through the secondment of the AE Executive Director,
• EUR 53,850 in membership fees,
• EUR 12,000 from the Luxembourg member organisation by providing the offices of Alzheimer Europe free of rent,
• EUR 12,236.60 from member organisations covering the travel expenses of AE Board members to attend Board meetings,
• EUR 31,200 in co-financing from Board members and representatives of member organisations in time donated to the organisation (at EUR 300 per day).

Deferred income

In 2011, Alzheimer Europe was able to contribute EUR 110,406.35 to its core activities which came from deferred income in 2010.

Individuals

In 2011, AE received EUR 81,714.30 from individuals which can be broken down as follows:

• EUR 79,643.99 in conference registrations,
• EUR 1,303.38 in publication sales and
• EUR 766.93 in donations.

Corporate support

In 2011, Alzheimer Europe received EUR 60,500 from corporate sources as core-funding which can be broken down as follows:

• EUR 15,000 from Bayer, EUR 10,000 from Janssen, Lilly and Pfizer, EUR 7,500 from Sanofi-Aventis and EUR 5,000 from SCA Global Hygiene as support to the Alzheimer Europe Conference in Warsaw,
• EUR 3,000 from Mazars which carried out the audit of the organisation’s accounts free of charge and

Foundations and organisations

The EUR 28,600 which Alzheimer Europe received in 2011 from foundations and other non-profit organisations can be broken down as follows:

• EUR 5,000 from Fondation Médéric Alzheimer and Fondation Roi Baudouin to support the Alzheimer Europe Conference in Warsaw,
• EUR 9,000 from Fondation Médéric Alzheimer to support the legal rights activities of Alzheimer Europe,
• EUR 9,600 in donated time by experts involved in the ethical work of Alzheimer Europe (at EUR 300 per day)..

Bank interest and similar

In 2011, Alzheimer Europe had an income of EUR 1,804.27 from bank interest and similar income.

Other income

In 2011, EUR 9,061.13 came from other sources not mentioned above.

Funding of public affairs activities (EUR 207,012.08)

In 2011, Alzheimer Europe received EUR 207,012.08 for its public affairs activities, of which

• EUR 206,032.60 (99.53%) came from corporate sponsors and
• EUR 979.48 (0.47%) from other income.

Corporate support

The corporate support received by Alzheimer Europe for its public affairs activities in 2011 (EUR 206,032.90) can be broken down as follows:

• Pfizer, Janssen and Lilly each contributed EUR 40,000 as a gold sponsor,
• GlaxoSmithKline contributed EUR 35,000 in support,
• Lundbeck and Sanofi contributed EUR 20,000 each as silver sponsors and
• SCA Global Hygiene contributed EUR 10,000 as a bronze sponsor.

In addition, AE received EUR 108.80 in travel support from Pfizer and EUR 923.80 as travel support and honoraria from GlaxoSmithKline.

Other income

In 2011, EUR 979.48 came from sources not included above.

Funding of Value of Knowing-project (EUR 318,045.81)

In 2011, the funding of the Value of Knowing project was composed as follows:

• EUR 125.000 (39.30%) from corporate funding,
• EUR 192,145.81 (60.41%) from reserves brought forward from the financial year 2010 and
• EUR 900 (0.28%) from member organisations.

Corporate support

In 2011, AE received an educational grant of EUR 125,000 from Bayer Healthcare for its Value of Knowing project.

Deferred income

In 2011, Alzheimer Europe contributed EUR 192,145.81 to the Value of knowing project from income received on account in 2010.

Foundations and organisations

EUR 900 of the income of the Value of Knowing project consisted in time donated by Board members to the project (at EUR 300 per day).

Overall funding

The following table lists all sources of income received in 2011.

In line with the policy of the European Medicines Agency on transparency requirements for accredited patients’ organisations, this is presented in total amounts as well as in terms of percentages of the overall income of the organisation.